Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Goodwill and Intangible Asset Disclosure
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The composition of intangible assets and goodwill exhibits notable shifts over the five-year period. Customer relationships represent the largest component of identifiable intangible assets, demonstrating relative stability with a slight upward trend from US$22,802 million in 2021 to US$23,290 million in 2025. Product technology, conversely, shows a consistent decline, decreasing from US$6,041 million to US$5,196 million over the same timeframe. Trade names experienced modest fluctuations, increasing from US$1,635 million in 2022 to US$1,804 million in 2025.
Definite-lived acquisition-related intangible assets, both gross and net of accumulated amortization, generally decreased between 2021 and 2024, before showing a slight increase in 2025. The gross value decreased from US$31,625 million to US$30,991 million between 2021 and 2024, then rose to US$31,374 million in 2025. Accumulated amortization increased steadily throughout the period, from -US$12,747 million to -US$16,771 million, resulting in a net decrease in definite-lived acquisition-related intangible assets from US$18,878 million to US$14,603 million between 2021 and 2025. Indefinite-lived acquisition-related intangible assets remained constant at US$1,235 million throughout the period.
Goodwill experienced a substantial increase, rising from US$41,924 million in 2021 to US$49,362 million in 2025. This growth is particularly pronounced between 2023 and 2025. The combined value of acquisition-related intangible assets and goodwill followed a similar pattern, decreasing from US$62,037 million in 2021 to US$58,638 million in 2022, then increasing to US$65,200 million in 2025.
- Goodwill Trend
- A consistent upward trend in goodwill is observed, indicating continued acquisitions or a lack of impairment charges. The increase from US$44,020 million in 2023 to US$49,362 million in 2025 suggests significant activity in the latter years of the period.
- Definite-Lived Intangibles
- The decline in net definite-lived acquisition-related intangible assets, driven by increasing accumulated amortization, suggests the systematic expensing of the value of acquired assets over their useful lives. The slight increase in 2025 may indicate recent acquisitions offsetting amortization.
- Intangible Asset Composition
- Customer relationships consistently represent the largest portion of identifiable intangible assets. The decreasing value of product technology may warrant further investigation to understand the underlying reasons, such as obsolescence or changes in business strategy.
- Overall Trend
- While definite-lived intangible assets decreased overall, the substantial growth in goodwill suggests a strategic focus on acquisitions contributing to the overall increase in acquisition-related intangible assets and goodwill.
Adjustments to Financial Statements: Removal of Goodwill
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
An examination of the financial information reveals significant discrepancies between reported and adjusted total assets and shareholders’ equity over the five-year period. The adjustments appear to primarily relate to the removal of goodwill and intangible assets, resulting in substantially lower adjusted figures.
- Total Assets
- Reported total assets demonstrate a general upward trend from $95.123 billion in 2021 to $110.343 billion in 2025, with a slight decrease observed in 2024. However, adjusted total assets present a markedly different picture. They begin at $53.199 billion in 2021 and fluctuate, peaking at $55.958 billion in 2022 before declining to $51.468 billion in 2024, and then increasing to $60.981 billion in 2025. The difference between reported and adjusted total assets widens over time, indicating an increasing amount of goodwill and intangibles being removed in the adjustments.
- Shareholders’ Equity
- Reported shareholders’ equity consistently increases throughout the period, moving from $40.793 billion in 2021 to $53.407 billion in 2025. Conversely, adjusted shareholders’ equity begins with a negative value of -$1.131 billion in 2021. It then becomes positive in 2022 and continues to grow, reaching $4.045 billion in 2025. This suggests a substantial initial write-down of goodwill and intangibles impacting equity, followed by a more moderate positive trend in adjusted equity as the period progresses. The magnitude of the adjustment to equity is considerably smaller than the adjustment to total assets.
The substantial differences between reported and adjusted figures highlight the significant impact of goodwill and intangible assets on the company’s reported financial position. The negative adjusted shareholders’ equity in 2021 is a notable observation, indicating a considerable prior accumulation of goodwill and intangibles that were subsequently deemed impaired or otherwise adjusted. The increasing adjusted total assets in 2025, while still below the reported value, suggest a potential stabilization or reduction in the rate of goodwill and intangible asset write-downs.
- Asset and Equity Relationship
- The ratio of adjusted shareholders’ equity to adjusted total assets is consistently low, starting at a negative value in 2021 and gradually increasing to approximately 6.65% in 2025. This indicates a relatively high degree of reliance on debt or other non-equity financing, or a significant proportion of assets not represented by equity, even after the adjustments. The increasing trend suggests a strengthening of the equity base relative to the adjusted asset base, but remains comparatively low.
Thermo Fisher Scientific Inc., Financial Data: Reported vs. Adjusted
Adjusted Financial Ratios: Removal of Goodwill (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The financial metrics demonstrate a significant impact from adjusting for goodwill and intangible assets. Reported ratios generally exhibit more moderate fluctuations compared to their adjusted counterparts, highlighting the substantial influence of these non-cash assets on overall financial performance as traditionally measured.
- Total Asset Turnover
- Reported total asset turnover remained relatively stable between 0.41 and 0.46 over the period, with a slight decrease to 0.40 in the final year. In contrast, the adjusted total asset turnover consistently exceeded the reported figures, ranging from 0.74 to 0.83, indicating a more efficient use of assets when goodwill is excluded from the asset base. The adjusted ratio also shows a similar decreasing trend in the final year.
- Financial Leverage
- Reported financial leverage decreased from 2.33 to 1.96 between 2021 and 2024, before increasing slightly to 2.07 in 2025. The adjusted financial leverage, however, presents a markedly different picture. It begins at 20.11 in 2022 and decreases to 13.79 in 2024, then rises to 15.08 in 2025. This substantial difference suggests that a significant portion of the company’s assets is comprised of goodwill, which, when removed, reveals a considerably different capital structure.
- Return on Equity (ROE)
- Reported ROE experienced a consistent decline from 18.94% in 2021 to 12.55% in 2025. The adjusted ROE, beginning in 2022, is substantially higher, peaking at 249.82% and decreasing to 165.74% in 2025. This dramatic increase and subsequent decline demonstrate the considerable impact of goodwill on reported equity. The adjusted ROE remains significantly above the reported ROE throughout the observed period.
- Return on Assets (ROA)
- Reported ROA also showed a downward trend, decreasing from 8.12% in 2021 to 6.08% in 2025. The adjusted ROA, while also exhibiting a decreasing trend from 14.52% to 10.99%, consistently remained above the reported ROA. This indicates that the underlying operational profitability, when considered without the influence of goodwill, is higher than what the reported ROA suggests.
Overall, the adjusted ratios reveal a business with potentially higher efficiency and profitability than indicated by the standard financial statements. The large discrepancies between reported and adjusted figures underscore the importance of considering the impact of goodwill and intangible assets when evaluating the company’s financial performance and position.
Thermo Fisher Scientific Inc., Financial Ratios: Reported vs. Adjusted
Adjusted Total Asset Turnover
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
2025 Calculations
1 Total asset turnover = Revenues ÷ Total assets
= ÷ =
2 Adjusted total asset turnover = Revenues ÷ Adjusted total assets
= ÷ =
An examination of the financial information reveals distinct trends in both reported and adjusted total assets, alongside their corresponding turnover ratios. Reported total assets experienced a general increase from 2021 to 2023, followed by a decrease in 2024, and a substantial increase in 2025. Adjusted total assets mirrored this pattern, though the magnitude of change differed. The adjusted total asset turnover ratio demonstrates a more consistent pattern of fluctuation.
- Reported Total Assets
- Reported total assets increased from US$95,123 million in 2021 to US$97,154 million in 2022, and further to US$98,726 million in 2023. A decline to US$97,321 million was noted in 2024, before a significant rise to US$110,343 million in 2025. This suggests potential acquisitions or significant capital investments in 2025.
- Adjusted Total Assets
- Adjusted total assets increased from US$53,199 million in 2021 to US$55,958 million in 2022, then decreased slightly to US$54,706 million in 2023. A more pronounced decrease was observed in 2024, falling to US$51,468 million, followed by an increase to US$60,981 million in 2025. The adjustments made to total assets appear to be impacting the overall asset base, and the 2025 increase aligns with the reported total asset growth.
- Reported Total Asset Turnover
- The reported total asset turnover ratio fluctuated between 0.41 and 0.46 over the period. It began at 0.41 in 2021, rose to 0.46 in 2022, decreased to 0.43 in 2023, increased slightly to 0.44 in 2024, and then decreased to 0.40 in 2025. This indicates a relatively stable, but slightly declining, efficiency in generating revenue from reported assets.
- Adjusted Total Asset Turnover
- The adjusted total asset turnover ratio exhibited a stronger trend. It increased from 0.74 in 2021 to 0.80 in 2022, decreased to 0.78 in 2023, rose to a peak of 0.83 in 2024, and then decreased to 0.73 in 2025. The higher values suggest that, when considering the adjustments to total assets, the company demonstrates a more efficient use of its asset base in generating revenue. The decrease in 2025, while present, is less pronounced than the decrease in the reported turnover ratio.
The divergence between the reported and adjusted turnover ratios suggests that the adjustments to total assets are significantly impacting the assessment of asset efficiency. The consistent increase in the adjusted ratio until 2024 indicates improved operational efficiency when intangible assets and goodwill are considered. The decline in both ratios in 2025 warrants further investigation to determine the underlying causes.
Adjusted Financial Leverage
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
2025 Calculations
1 Financial leverage = Total assets ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
An examination of the financial information reveals notable trends in asset valuation and associated leverage metrics between 2021 and 2025. Reported total assets demonstrate a generally increasing trajectory, with a slight decrease observed in 2024 before recovering significantly in 2025. However, adjusted total assets present a more nuanced picture, exhibiting fluctuations throughout the period. Shareholders’ equity, both reported and adjusted, generally increased over the five-year period.
- Adjusted Total Assets
- Adjusted total assets increased from US$53,199 million in 2021 to US$55,958 million in 2022, then decreased to US$54,706 million in 2023 and further to US$51,468 million in 2024. A substantial increase to US$60,981 million is then observed in 2025. This suggests potential changes in the valuation of goodwill and intangible assets impacting the adjusted asset base.
- Adjusted Shareholders’ Equity
- Adjusted shareholders’ equity began at a negative value of US$-1,131 million in 2021, indicating a significant offset to equity related to the adjustments made. It then became positive in 2022, reaching US$2,782 million, and remained positive through 2025, increasing to US$4,045 million. This positive trend suggests a strengthening of the equity position after adjustments.
- Adjusted Financial Leverage
- Adjusted financial leverage shows a dramatic increase in 2022, reaching 20.11, before decreasing to 20.15 in 2023. A substantial decrease to 13.79 is observed in 2024, followed by an increase to 15.08 in 2025. The high leverage ratios in the earlier years of the period, coupled with the subsequent decline, warrant further investigation into the nature of the adjustments made to assets and equity. The fluctuations suggest a sensitivity of the leverage ratio to changes in the adjusted asset and equity values.
Reported financial leverage consistently decreased from 2.33 in 2021 to 1.96 in 2024, before increasing slightly to 2.07 in 2025. This contrasts with the volatility observed in the adjusted financial leverage, highlighting the impact of the adjustments on the overall leverage profile. The divergence between reported and adjusted leverage suggests that a significant portion of the company’s assets and equity are subject to adjustments that materially affect its financial risk profile.
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
2025 Calculations
1 ROE = 100 × Net income attributable to Thermo Fisher Scientific Inc. ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= 100 × ÷ =
2 Adjusted ROE = 100 × Net income attributable to Thermo Fisher Scientific Inc. ÷ Adjusted total Thermo Fisher Scientific Inc. shareholders’ equity
= 100 × ÷ =
Shareholders’ equity, both as reported and adjusted, demonstrates a consistent upward trend over the five-year period. However, significant divergence exists between the reported and adjusted equity figures, particularly in the earlier years. This difference substantially impacts the calculated return on equity.
- Shareholders’ Equity
- Reported total shareholders’ equity increased steadily from US$40,793 million in 2021 to US$53,407 million in 2025, indicating consistent growth in the company’s net assets. Adjusted total shareholders’ equity, however, begins at a negative value in 2021 before becoming positive in 2022 and continuing to increase, though at a lower magnitude than the reported equity. The initial negative adjusted equity suggests the presence of substantial goodwill or intangible assets that are being adjusted for in the calculation.
- Reported Return on Equity (ROE)
- Reported ROE experienced a decline from 18.94% in 2021 to 12.55% in 2025. This downward trend suggests a decreasing profitability relative to shareholders’ equity, even as equity itself increases. The decline is relatively consistent year-over-year, indicating a sustained shift in profitability.
- Adjusted Return on Equity (ROE)
- Adjusted ROE exhibits extremely high values in 2022 (249.82%) and 2023 (220.81%), followed by a decrease to 169.79% in 2024 and 165.74% in 2025. The initial high values are a direct consequence of the significant adjustment to shareholders’ equity in 2022, moving from a negative value to a positive one. While still substantial, the subsequent decline in adjusted ROE suggests that the impact of the equity adjustment is diminishing over time, and profitability, even when adjusted, is moderating. The large difference between reported and adjusted ROE highlights the sensitivity of this metric to the treatment of goodwill and intangible assets.
The substantial difference between reported and adjusted ROE warrants further investigation into the nature and magnitude of the adjustments made to shareholders’ equity. The initial negative adjusted equity and subsequent large positive adjustments suggest a significant impact from intangible assets or goodwill, potentially related to acquisitions. The decreasing, but still elevated, adjusted ROE indicates that while the underlying business may be generating strong returns relative to the adjusted equity base, the reported ROE provides a more conservative view of profitability.
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
2025 Calculations
1 ROA = 100 × Net income attributable to Thermo Fisher Scientific Inc. ÷ Total assets
= 100 × ÷ =
2 Adjusted ROA = 100 × Net income attributable to Thermo Fisher Scientific Inc. ÷ Adjusted total assets
= 100 × ÷ =
The period between 2021 and 2025 demonstrates fluctuating performance when examining both reported and adjusted return on assets. Reported total assets generally increased over the period, with a slight decrease observed in 2024 before a substantial rise in 2025. However, adjusted total assets show a more volatile pattern, decreasing in 2024 before increasing significantly in 2025.
- Reported Return on Assets (ROA)
- Reported ROA experienced a consistent decline from 8.12% in 2021 to 6.07% in 2023. A modest recovery to 6.51% occurred in 2024, followed by a slight decrease to 6.08% in 2025. This suggests a general weakening in profitability relative to reported total assets, with limited improvement in the most recent year.
- Adjusted Return on Assets (ROA)
- Adjusted ROA exhibited a similar downward trend to the reported ROA, decreasing from 14.52% in 2021 to 10.96% in 2023. A notable increase to 12.31% was observed in 2024, but this was followed by a decrease to 10.99% in 2025. The adjusted ROA consistently remained higher than the reported ROA throughout the period, indicating that the inclusion of adjustments significantly impacts profitability assessment.
- Relationship between Reported and Adjusted ROA
- The difference between reported and adjusted ROA remained substantial throughout the analyzed period. This suggests that goodwill and intangible assets, which are likely the focus of the adjustments, have a considerable impact on the overall return on assets calculation. The consistent higher value of the adjusted ROA implies that the reported figures may not fully reflect the underlying economic profitability of the asset base when considering these items.
The increase in both reported and adjusted total assets in 2025, coupled with the relatively stable adjusted ROA, suggests that the company is deploying capital, but the impact on profitability, as measured by adjusted ROA, is not proportionally increasing. Further investigation into the nature of the asset increases and the adjustments made to arrive at the adjusted ROA would be beneficial.